|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||45.32 - 46.23|
|52 Week Range||29.23 - 47.04|
|Beta (3Y Monthly)||2.02|
|PE Ratio (TTM)||43.37|
|Earnings Date||Apr 29, 2019 - May 3, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.40|
Moody's Investors Service ("Moody's") downgraded Catalent Pharma Solutions, Inc. ("Catalent")'s senior secured credit ratings to Ba3 from Ba2. At the same time, Moody's affirmed Catalent's B1 Corporate Family Rating (CFR), the B1-PD Probability of Default Rating, and the B3 senior unsecured rating.
Catalent (CTLT) delivered earnings and revenue surprises of 8.89% and -4.14%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Catalent Inc NYSE:CTLTView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for CTLT with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding CTLT totaled $306 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The Somerset, New Jersey-based company said it had net income of 22 cents per share. Earnings, adjusted for one-time gains and costs, were 49 cents per share. The results topped Wall Street expectations. ...
SOMERSET, N.J.-- -- Q3'19 revenue of $617.5 million decreased 2% as-reported, but increased 2% in constant currency, from Q3'18, while Q3'19 YTD revenue of $1,792.3 million increased 1% as-reported, or 3% in constant currency, from the prior-year period. Double-digit organic segment EBITDA growth within Biologics and Specialty Drug Delivery, Oral Drug Delivery and Clinical Supply Services segments; ...
Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A market correction in the fourth quarter, spurred by a number of global macroeconomic concerns and rising interest rates ended up having a negative impact on the markets and many hedge funds as a result. The stocks of smaller companies were especially hard hit during this time as investors fled to investments seen as being […]
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Catalent Pharma Solutions, Inc. New York, April 17, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Catalent Pharma Solutions, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
New York, April 17, 2019 -- Moody's Investors Service ("Moody's") commented that Catalent Pharma Solutions, Inc.'s proposed acquisition of Paragon Bioservices for $1.2 billion in cash will increase the company's financial leverage, a credit negative. For additional information please refer to Moody's Issuer Comment on Catalent Pharma Solutions available on www.moodys.com. Headquartered in Somerset, New Jersey, Catalent Pharma Solutions, Inc. is a leading provider of development solutions and advanced delivery technologies for drugs, biologics and consumer health products.
Paragon, backed by private-equity firms Camden Partners and NewSpring Capital, focuses on developing and making complex biopharmaceuticals for its clients and is expected to bring in more than $200 million in revenue this year, Catalent said. "Paragon's unparalleled expertise in the rapidly growing market of gene therapy manufacturing will be a transformative addition to our business that we believe will accelerate our long-term growth," Catalent Chief Executive Officer John Chiminski said in a statement. Most emerging drug companies lack the resources to manufacture drugs and rely on contract organizations such as Catalent and Paragon to make the drugs using their technology.
announced Monday that it has agreed to buy closely held Paragon Bioservices for $1.2 billion in cash, the latest deal in the burgeoning gene-therapy drug area. The Wall Street Journal had reported earlier Monday that Catalent would announce the all-cash deal for Paragon, paving the way for its entry into the burgeoning gene-therapy drug market. Catalent, which develops and manufactures drugs for pharmaceutical companies, had about $2.5 billion in sales last year.
Gene therapy deal news continues to trickle in after Catalent Inc (NYSE: CTLT) announced an agreement to buy another gene and cell therapy CDMO. Catalent, which provides technologies and integrated solutions for biologic and biosimilar development, said it has entered into a definitive agreement to buy Paragon Services, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion in cash. Catalent expects to fund the transaction partly from its existing credit facilities and partly from an issuance of preferred equity.
Check out the companies making headlines before the bell: Goldman Sachs GS — The investment bank reported quarterly profit of $5.71 per share , beating the consensus estimate of $4.89. Revenue fell short of forecasts, however.
Catalent Inc. said Monday it has agreed to acquire Paragon Bioservices Inc. for $1.2 billion in cash. Calent, a provider of delivery technologies for drugs, biologics and consumer health products, said it expects the deal to close in the second quarter. Privately held Paragon is a viral vector development and manufacturing partner for gene therapies. "Paragon brings specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used delivery system for gene therapy, as well as unique capabilities in GMP plasmids and lentivirus vectors," Catalent said in a statement. Paragon is expected to generate more than $200 million in revenue in 2019 with nearly 90% of that sum already in signed contracts. The deal is expected to boost Catalent's adjusted net income per share in the second full fiscal year after closing. Catalent will finance the deal with the proceeds of a $650 million term loan and by issuing $650 million of convertible preferred stock to funds tied to Leonard Green and Partners LP. Shares were not yet active premarket, but have fallen 2.4% in the last 12 months, while the S&P 500 has gained 9.5%.
Catalent Inc said on Monday it would buy privately held gene therapy-focused Paragon Bioservices Inc in an all-cash deal for $1.2 billion. Paragon, backed by private-equity firms Camden Partners and NewSpring ...
SOMERSET, N.J. and BALTIMORE, April 15, 2019 /PRNewswire/ -- Catalent, Inc. (CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, today announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion. "Paragon's unparalleled expertise in the rapidly growing market of gene therapy manufacturing will be a transformative addition to our business that we believe will accelerate our long-term growth.
Catalent, Inc. (CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, today announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion. “Paragon’s unparalleled expertise in the rapidly growing market of gene therapy manufacturing will be a transformative addition to our business that we believe will accelerate our long-term growth.
An all-cash deal between the companies is expected to be announced on Monday morning and would help Catalent expand its capabilities to develop specialized and costly gene therapy treatments, the Journal said. Catalent and Paragon did not immediately respond to requests for comment on Sunday. Drug companies have been moving aggressively into gene therapy, where treatments for rare, inherited diseases command some of the highest prices in medicine.
Buying a low-cost index fund will get you the average market return. But if you invest in individual stocks, some are likely to underperform. Unfortunately for shareholders, while the Catalent, Inc. (NYSE:CTLT) share pri...
Catalent, Inc. (CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the third quarter of fiscal year 2019 ended March 31, 2019, before the market open on Tuesday, May 7, 2019. Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com. A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast.